ReviewFrontiers in human neuroscience2021
Electrophysiological Biomarkers of Epileptogenicity in Alzheimer's Disease.
Review in Frontiers in human neuroscience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Functional and structural retinal alterations in Alzheimer's disease: insights from photopic negative response (PhNR) and OCT-based analysis.Documenta ophthalmologica. Advances in ophthalmology · 2026Article
- Mapping and modulating brain dynamics in aging and neurodegeneration with electroencephalography and integrated neurotechnologies in primates.Frontiers in neuroscience · 2026Review
- Metaheuristic-driven dual-layer model for classifying Alzheimer's disease stages.Frontiers in computational neuroscience · 2026Article
- Revealing the nervous system requirements of Alzheimer disease risk genes in Drosophila.American journal of human genetics · 2025Article
- Bridging Epilepsy and Cognitive Impairment: Insights from EEG and Clinical Observations in a Retrospective Case Series.Journal of personalized medicine · 2025Article
- Revealing the nervous system requirements of Alzheimer's disease risk genes inbioRxiv : the preprint server for biology · 2025Article
- Alzheimer's Disease and Epilepsy: Exploring Shared Pathways and Promising Biomarkers for Future Treatments.Journal of clinical medicine · 2024Review
- Local signal variability and functional connectivity: Sensitive measures of the excitation-inhibition ratio?Cognitive neurodynamics · 2024Article
- Functional network disruption in cognitively unimpaired autosomal dominant Alzheimer's disease: a magnetoencephalography study.Brain communications · 2024Article
- Network Hyperexcitability in Early Alzheimer's Disease: Is Functional Connectivity a Potential Biomarker?Brain topography · 2023Article
- Resting-state oscillations reveal disturbed excitation-inhibition ratio in Alzheimer's disease patients.Scientific reports · 2023Article
- Review
- The fate of interneurons, GABABrain pathology (Zurich, Switzerland) · 2023Review
- Oxidative Stress as a Potential Mechanism Underlying Membrane Hyperexcitability in Neurodegenerative Diseases.Antioxidants (Basel, Switzerland) · 2022Review
- The Significance of Subclinical Epileptiform Activity in Alzheimer's Disease: A Review.Frontiers in neurology · 2022Review
- The clinical correlation between Alzheimer's disease and epilepsy.Frontiers in neurology · 2022Review
- Governance of the clinical pathway and management of the patient suffering from epilepsy and drug-resistant epilepsy.Global & regional health technology assessmentReview
- Immune effector cell-associated neurotoxicity syndrome: integrative mechanisms, predictive biomarkers, and translational pathways for prevention in CAR T-cell therapy.Frontiers in neurologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cortical network hyperexcitability is an inextricable feature of Alzheimer's disease (AD) that also might accelerate its progression. Seizures are reported in 10-22% of patients with AD, and subclinical epileptiform abnormalities have been identified in 21-42% of patients with AD without seizures. Accurate identification of hyperexcitability and appropriate intervention to slow the compromise of cognitive functions of AD might open up a new approach to treatment. Based on the results of several studies, epileptiform discharges, especially those with specific features (including high frequency, robust morphology, right temporal location, and occurrence during awake or rapid eye movement states), frequent small sharp spikes (SSSs), temporal intermittent rhythmic delta activities (TIRDAs), and paroxysmal slow wave events (PSWEs) recorded in long-term scalp electroencephalogram (EEG) provide sufficient sensitivity and specificity in detecting cortical network hyperexcitability and epileptogenicity of AD. In addition, magnetoencephalogram (MEG), foramen ovale (FO) electrodes, and computational approaches help to find subclinical seizures that are invisible on scalp EEGs. We performed a comprehensive analysis of the aforementioned electrophysiological biomarkers of AD-related seizures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.